Press

1. IntelliDose Launches IntelliScribe March 2, 2010
2. IntrinsiQ Sharpens Cancer Treatment Analysis February 10, 2010
3. Dayton Physicians Commits to Clinical Excellence by Partnering with IntelliDose February 2, 2010
4. IntelliDose Exhibiting at Fifth Annual Community Oncology Conference February 5–6, 2010
5. New York cancer care center uses automation to handle coding, reimbursement January 29, 2010
6. Tarceva Reprieve? FDA Delay Could Mean Little Either Way January 25, 2010
7. WWMR Vice President Invited to Speak at PBIRG Fall Biotech Workshop December 7, 2009
8. Panel Advises on Clinical Pathways: What, Why, and How November, 2009
9. IntrinsiQ Expands Executive Team November 3, 2009
10. IntelliDose Exhibiting at North Carolina Oncology Management Society 2009 Fall Conference November 18 to 20, 2009
11. Opportunity reconsidered: maintenance therapy in oncology October, 2009
12. IntrinsiQ Study: Oncologists Overlook Maintenance Therapy Option – More Often than They Realize September 15, 2009
13. Industry Thought Leaders: A Discussion with Jeff Forringer, President of IntrinsiQ, LLC August 2009
14. Are CPOEs worth the investment? August 2009
15. Information Technology: Tracking the Evolution of Oncology Drug Prescribing August 2009
16. Rich Gray, General Manager of IntelliDose, to Speak at ACCC 26th National Oncology Economics Conference September 22 to 25, 2009
17. IntelliDose Exhibiting at eClinicalWorks 2009 National Users Conference September 12 to 15, 2009
18. Jeff Forringer, President of IntrinsiQ, to Speak at the Magellan/ICORE 6th Annual Oncology Summit September 11, 2009
19. IntelliDose Exhibiting at GE Centricity User Group Fall Conference August 28 and 29, 2009
20. How Much Should Cancer Drugs Cost: Landmark Cornell University Study Sheds New Light on Old Assumptions August 4, 2009
21. IntrinsiQ Sponsors Cancer Center Business Summit October 8-9, 2009
22. The First Step to a Paperless Practice July 1, 2009
23. On the Move – Spotlight on Jeff Forringer June 19, 2009
24. Specialized chemotherapies increase market share, cost of care June 2009
25. IntrinsiQ Acquires Market Research Firm WWMR June 9, 2009
26. IntrinsiQ Appoints New Executive Team May 12, 2009
27. IntrinsiQ's IntelliDose May 2009
28. The real cost of treating off-label and off-guidelines March 2009
29. NewsMakers March 2009
30. Small mistakes, huge consequences; Onc-specific software improves safety February 2009
31. Safe Handling; The Right Drug, Right Dose, Right Patient January/February 2009
32. Automated Oncology February 2009
33. Still Using Paper and Pen? January 2009
34. OnCare Hawaii Selects IntelliDose for Oncology Patient Safety and Practice Efficiency January 6, 2009
35. Safe Handling December 2008
36. Market Opportunity in Lung Cancer December 2008
37. Cancer Center of South Florida Selects IntelliDose for All-Electronic Practice November 3, 2008
38. IntrinsiQ Launches IntelliDose 3.8 October 27, 2008
39. Technology: Can Oncology EMRs Improve Quality? September 2008
40. IntrinsiQ Builds Out Its Oncology-Products Market Analytics September 2008
41. IntrinsiQ Wins 3 Top Honors from Inc. Magazine September 9, 2008
42. New Reporting from IntrinsiQ Measures Impact of Key Events on Oncology Drug Usage September 2, 2008
43. High Drug Costs a Factor in Cancer Care August 28, 2008
44. Pharmawire analysis: Cyclacel's seliciclib comes under physician scrutiny August 2008
45. DSS Licenses IntelliDose to Standardize VA Oncology Practices August 18, 2008
46. Buried Treasure June 23, 2008
47. Data from the Doctor April 15, 2008
48. IntrinsiQ LLC - Dose of Success March 7, 2008
49. IntelliCost Provides Cost of Therapy Insight for Sizing New Market Opportunities February 13, 2008
50. Software application aims to eliminate human error in chemotherapy dosing January 11, 2008
51. Oncologists Nationwide Choose IntelliDose for Clinical Safety and Efficiency November 28, 2007
52. IntrinsiQ Expands Oncology’s Gold-Standard for Patient Data Collection September 25, 2007
53. IntelliDose to Participate in ASCO EHR Symposium July 19, 2007
54. GE Healthcare and IntrinsiQ Announce Collaboration to Link Clinical Oncology Information within Patient Electronic Medical Records May 31, 2007
55. IntelliDose® Unveils IntelliCharge — Automated Encounter Charge Capture Improves Control and Billing of Costly Chemotherapy Drugs May 31, 2007
56. PRA International and IntrinsiQ Research Enter Exclusive Agreement for Oncology Patient Treatment Data March 19, 2007
57. Pulse and IntrinsiQ Sign Strategic Agreement January 16, 2007
58. IMS, IntrinsiQ Research Establish Strategic Alliance to Deliver Global, Clinically Rich Oncology Market Intelligence August 2, 2006
59. Accel-KKR Acquires Majority Stake in IntrinsiQ June 20, 2006

FOR IMMEDIATE RELEASE:

Accel-KKR Acquires Majority Stake In IntrinsiQ

Menlo Park, CA and Boston, MA — June 20, 2006 — Accel-KKR, a technology-focused private equity investment firm, today announced its acquisition of a majority equity stake in IntrinsiQ, the national leader in medical oncology care software and the only source for automated longitudinal data on trends in cancer drug usage. Financial terms of the transaction were not disclosed.

Through its IntrinsiQ Research and IntrinsiQ Financial businesses, IntrinsiQ, originally founded in 1996 and headquartered in Boston, Massachusetts, is the leading provider of oncology market data and business analytics to the pharmaceutical/biotechnology industries, as well as financial institutions. The company’s major clients include, among others, BMS, Genentech, Pfizer, and Sanofi-Aventis.

The company also provides proprietary medical oncology care software, sold under its market- leading IntelliDoseTM brand, which manages the clinical care practice of oncology from the assignment of therapy, to the calculation of chemotherapy doses, to the documentation of care. The company currently has physician clients across 36 states — including in some of the most prestigious cancer centers in the country — and maintains records for more than 13,000 patients and 115,000 oncology-related drug administrations per month.

Brent Clough, CEO of IntrinsiQ, said, “Accel-KKR’s investment in our enterprise is a reflection of our tremendous progress, as well as the significant growth prospects of all of our company’s business lines. Accel-KKR’s track record as the preferred partner of management teams of closely-held businesses in the technology sector made the firm the logical choice for us when we determined that we had reached an appropriate point in our development to seek a financial and strategic partner.”

Tom Barnds, Managing Director of Accel-KKR, said, “We are delighted with this transaction, which represents our first investment in the healthcare technology arena, and bears all of the hallmarks of an outstanding platform on which to build an even larger and more profitable business. The high natural barriers to entry in this industry further reinforce the company’s leadership position in what is a highly fragmented market. Equally important, the company has a talented management team and employee base, as well as a robust pipeline of additional offerings and product enhancements, the roll out of which we intend to accelerate in the coming months and years.”

Rob Palumbo, Managing Director of Accel-KKR, added, “We are also delighted to undertake, once more, a recapitalization of a founder-owned business. This acquisition marks our fourth such transaction, and our third in the past eleven months alone. We take great pride in the leadership position we have achieved in this space, and we will continue to aggressively pursue other such transactions going forward.” Accel-KKR Acquires Majority Stake In IntrinsiQ

Under the terms of the transaction, Tom Barnds, Ben Bisconti, Rob Palumbo, and Jason Michael Klein from Accel-KKR, and Brent Clough and Dr. Howard Silverman, M.D., the company’s founder, Chief Technology Officer and former controlling equity holder, will join the Board of Directors of IntrinsiQ, effective immediately.

About Accel-KKR

Accel-KKR is a technology-focused private equity firm that invests primarily in technology businesses with $15 million to $150 million in revenue that are well positioned for top-line and bottom-line growth. At the core of Accel-KKR’s investment strategy is a commitment to developing strong partnerships with the management teams of its portfolio companies and a focus on building value through the contribution of unique financial, strategic, technical, and operational resources. Accel-KKR has a particular focus on the following transactions: Recapitalizations of family-owned or closely-held private companies, divisional buyouts of larger companies, and going-private transactions. For more information, please visit www.accel- kkr.com.

About IntrinsiQ

IntrinsiQ is the premier source for US oncology data and analysis. IntrinsiQ’s market leading software application, IntelliDoseTM, captures the treatment decisions and details of over 13,000 patients a month, creating an unrivaled database of accurate, detailed and timely information about the medical oncology care process. This database is the foundation of products and services that are designed to uniquely address the business issues and decisions to the pharmaceutical product manager, market researcher and financial analyst. For more information, please visit www.intrinsiq.com.

Contact

Joseph Kuo
Kekst and Company
212-521-4800

© 2010 IntrinsiQ, LLC